No Data
Haisco Pharmaceutical Group (002653.SZ) proposes a profit distribution plan for the first three quarters of 2024: a distribution of 1.35 yuan for every 10 shares.
On December 30, Gelonghui reported that Haisco Pharmaceutical Group (002653.SZ) announced the profit distribution plan for the first three quarters of 2024: it intends to distribute a cash dividend of 1.35 yuan (including tax) for every 10 shares based on the existing total share capital of 1,119,917,970 shares, totaling a cash dividend of 0.151 billion yuan.
Haisco Pharmaceutical Group (002653.SZ): A subsidiary has received acceptance notifications for two new indication IND applications for the innovative drug HSK44459 tablets.
On December 30th, Gelonghui reported that Haisco Pharmaceutical Group (002653.SZ) announced that its subsidiary Shanghai Haisco Shennuo Pharmaceutical Technology Co., Ltd. recently received the "Acceptance Notification" for HSK44459 tablets issued by the National Medical Products Administration. HSK44459 tablets are a brand new drug independently developed by the company with independent intellectual property rights for the treatment of psoriasis and atopic dermatitis. According to the National Medical Products Administration's announcement on the classification and application requirements for Chemical Drug registration (2020 No. 44), this product falls under Chemical Drug Class 1. Preclinical
Pinning Down Haisco Pharmaceutical Group Co., Ltd.'s (SZSE:002653) P/E Is Difficult Right Now
Haisco Pharmaceutical Group (002653.SZ) received industrial support funds of 43.9341 million yuan.
Haisco Pharmaceutical Group (002653.SZ) released an announcement that the company and its subsidiary Tibet Haize Marketing Management Co., Ltd. ("Tibet..."
The Three-year Decline in Earnings Might Be Taking Its Toll on Haisco Pharmaceutical Group (SZSE:002653) Shareholders as Stock Falls 6.9% Over the Past Week
Haisco Pharmaceutical Group (002653.SZ): has obtained the "Notice of Drug Clinical Trial Approval" for the innovative drug HSK46575 tablets.
On December 4th, Haisco Pharmaceutical Group (002653.SZ) announced that its subsidiary, Tibet Haisco Pharmaceutical Co., Ltd., recently received the "Drug Clinical Trial Approval Notice" issued by the National Medical Products Administration. The tablet is named HSK46575 Tablet and is intended for the treatment of prostate cancer. HSK46575 Tablet is a self-developed oral, potent, and highly selective small molecule inhibitor designed for the treatment of prostate cancer. Preclinical research results indicate that this product has a clear target, precise efficacy, and good safety profile, making it a highly promising small molecule drug with significant potential for development. The benefits/risks of clinical application.
What Haisco Pharmaceutical Group Co., Ltd.'s (SZSE:002653) 26% Share Price Gain Is Not Telling You
